Published in Invest New Drugs on September 21, 2012
Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol (2008) 2.36
Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid. Biochem Pharmacol (1998) 1.15
Preclinical in vivo antitumor activity of vinflunine, a novel fluorinated Vinca alkaloid. Cancer Chemother Pharmacol (1998) 1.13
Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumours. Ann Oncol (2003) 1.10
Pharmacokinetics of anticancer agents in patients with impaired liver function. Eur J Cancer (1998) 1.02
Pharmacokinetics of vinorelbine in patients with liver metastases. Clin Pharmacol Ther (1996) 0.95
Phase I study of vinflunine administered as a 10-minute infusion on days 1 and 8 every 3 weeks. Invest New Drugs (2006) 0.88
Pharmacokinetics, metabolites, and preclinical safety of vinflunine. Semin Oncol (2008) 0.85
Vinflunine. Drugs (2010) 0.82
Mild to moderate liver dysfunction does not require dose reduction of oral or intravenous vinorelbine: results of a pharmacokinetic study. Eur J Cancer (2009) 0.81
A simple and sensitive high-performance liquid chromatographic method for the determination of vinflunine and 4-O-deacetylvinflunine from human blood. Ther Drug Monit (2010) 0.81
Vinblastine (NSC-49842) plus vincristine (NSC-67574) given in intensive 3-day courses as therapy for lymphomas, sarcomas, and other neoplasms. Cancer Chemother Rep (1974) 0.80
Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie. N Engl J Med (1998) 4.93
Sterol regulatory element binding protein-1c is a major mediator of insulin action on the hepatic expression of glucokinase and lipogenesis-related genes. Proc Natl Acad Sci U S A (1999) 4.88
ADD1/SREBP-1c is required in the activation of hepatic lipogenic gene expression by glucose. Mol Cell Biol (1999) 3.63
Characterization of the role of AMP-activated protein kinase in the regulation of glucose-activated gene expression using constitutively active and dominant negative forms of the kinase. Mol Cell Biol (2000) 3.27
Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol Psychiatry (2002) 2.87
A method to quantify glucose utilization in vivo in skeletal muscle and white adipose tissue of the anaesthetized rat. Biochem J (1985) 2.77
Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol (1998) 2.52
Mechanisms by which carbohydrates regulate expression of genes for glycolytic and lipogenic enzymes. Annu Rev Nutr (1997) 2.48
Salvage transjugular intrahepatic portosystemic shunt for uncontrolled variceal bleeding in patients with decompensated cirrhosis. J Hepatol (2001) 2.43
AMP-activated protein kinase inhibits the glucose-activated expression of fatty acid synthase gene in rat hepatocytes. J Biol Chem (1998) 2.38
Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer (2002) 2.34
Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer. Ann Oncol (2014) 2.29
Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol (1996) 2.17
Adaptations of glucose and fatty acid metabolism during perinatal period and suckling-weaning transition. Physiol Rev (1992) 2.15
Prediction of the depressive effects of interferon alfa therapy by the patient's initial affective state. N Engl J Med (1999) 2.14
Sequential sorafenib and sunitinib for renal cell carcinoma. J Urol (2009) 2.12
Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie. Ann Oncol (2002) 2.03
Taxane-induced glaucoma. Lancet (1999) 2.02
Effects of fasting on tissue glucose utilization in conscious resting rats. Major glucose-sparing effect in working muscles. Biochem J (1987) 1.93
Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. Am J Transplant (2012) 1.88
Insulin effects on sterol regulatory-element-binding protein-1c (SREBP-1c) transcriptional activity in rat hepatocytes. Biochem J (2000) 1.78
Reduced-dose tacrolimus with mycophenolate mofetil vs. standard-dose tacrolimus in liver transplantation: a randomized study. Am J Transplant (2011) 1.75
Cholesterol, a cell size-dependent signal that regulates glucose metabolism and gene expression in adipocytes. J Biol Chem (2001) 1.74
Short- and long-term donor morbidity in right lobe living donor liver transplantation: 91 consecutive cases in a European Center. Am J Transplant (2011) 1.70
Adenovirus-mediated overexpression of sterol regulatory element binding protein-1c mimics insulin effects on hepatic gene expression and glucose homeostasis in diabetic mice. Diabetes (2001) 1.67
Regulation of lipogenic enzyme gene expression by nutrients and hormones. FASEB J (1994) 1.65
PrPSc accumulation in myocytes from sheep incubating natural scrapie. Nat Med (2004) 1.63
Glucose metabolism during lactation in the rat: quantitative and regulatory aspects. Am J Physiol (1983) 1.59
Glucose stimulation of lipogenic enzyme gene expression in cultured white adipose tissue. A role for glucose 6-phosphate. J Biol Chem (1992) 1.58
Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon alfa-2b therapy. J Clin Oncol (2000) 1.57
Real-time PCR on the first galactomannan-positive serum sample for diagnosing invasive aspergillosis in liver transplant recipients. Transpl Infect Dis (2008) 1.54
Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol (1995) 1.49
Orthotopic liver transplantation in fulminant and subfulminant hepatitis. The Paul Brousse experience. Ann Surg (1995) 1.45
Adjuvant therapy by BCG of non-Hodgkin's malignant lymphomas in a controlled trial: an update. Br J Haematol (1989) 1.39
[Adult to adult living-related liver transplantation. The Paul-Brousse Hospital preliminary experience]. Gastroenterol Clin Biol (2001) 1.38
Emergency orthotopic liver transplantation in two patients using one donor liver. Br J Surg (1989) 1.38
Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy. Psychoneuroendocrinology (2001) 1.37
Pregnancy-induced insulin resistance in the rat: assessment by glucose clamp technique. Am J Physiol (1984) 1.35
Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial. Ann Oncol (2005) 1.33
Immunoscintigraphy of colon carcinoma. J Nucl Med (1984) 1.31
Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study. Eur J Cancer (2011) 1.29
Hypoglycaemic effect of metformin in genetically obese (fa/fa) rats results from an increased utilization of blood glucose by intestine. Biochem J (1989) 1.28
Effect of anesthesia on glucose production and utilization in rats. Am J Physiol (1987) 1.27
Glucose utilization in vivo and insulin-sensitivity of rat brown adipose tissue in various physiological and pathological conditions. Biochem J (1986) 1.26
Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat. Diabetes (1997) 1.26
EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer. Br J Cancer (2003) 1.25
Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy. J Clin Oncol (1996) 1.25
Phase II trial with S-1 in chemotherapy-naïve patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG). Eur J Cancer (2003) 1.24
Obesity-related overexpression of fatty-acid synthase gene in adipose tissue involves sterol regulatory element-binding protein transcription factors. J Biol Chem (1998) 1.24
Timing and specificity of the cognitive changes induced by interleukin-2 and interferon-alpha treatments in cancer patients. Psychosom Med (2001) 1.20
Diabetes and inflammation: fundamental aspects and clinical implications. Diabetes Metab (2010) 1.19
Influence of exogenous fat and gluconeogenic substrates on glucose homeostasis in the newborn rat. Am J Physiol (1978) 1.18
First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma. Ann Oncol (2008) 1.18
Incidence of rejection and infection after liver transplantation as a function of the primary disease: possible influence of alcohol and polyclonal immunoglobulins. Hepatology (1996) 1.16
Risk model for severe anemia requiring red blood cell transfusion after cytotoxic conventional chemotherapy regimens. The Elypse 1 Study Group. J Clin Oncol (1999) 1.14
T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survival. Br J Cancer (2011) 1.14
Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma. Ann Oncol (2012) 1.12
Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumours. Ann Oncol (2003) 1.10
Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. Ann Oncol (2001) 1.08
[Rapid diagnosis of cytomegalovirus hepatitis after liver transplantation. Use of monoclonal antibody E13 directed against an early viral antigen]. Ann Pathol (1990) 1.08
Population pharmacokinetics of the novel anticancer agent E7070 during four phase I studies: model building and validation. J Clin Oncol (2002) 1.07
Regulation of lipogenic enzyme expression by glucose in liver and adipose tissue: a review of the potential cellular and molecular mechanisms. Adv Enzyme Regul (1996) 1.07
Single-agent gemcitabine is active in previously treated metastatic breast cancer. Oncology (2001) 1.07
Development of obesity in Zucker rats. Early insulin resistance in muscles but normal sensitivity in white adipose tissue. Diabetes (1987) 1.06
In vivo insulin resistance during pregnancy in the rat. Diabetologia (1980) 1.03
Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy. Ann Oncol (2011) 1.03
Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer. Ann Oncol (2009) 1.03
Incidence of large oesophageal varices in patients with cirrhosis: application to prophylaxis of first bleeding. Gut (1990) 1.02
Glucose transporter 2 (GLUT 2): expression in specific brain nuclei. Brain Res (1994) 1.02
Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer New Drug Development Group. Ann Oncol (2004) 1.01
Extended measures for controlling an outbreak of VIM-1 producing imipenem-resistant Klebsiella pneumoniae in a liver transplant centre in France, 2003-2004. Euro Surveill (2010) 1.01
Immunoscintigraphy of recurrences of gynecologic carcinomas. J Nucl Med (1987) 1.01
[Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study]. Rev Neurol (Paris) (2008) 1.01
Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group. J Clin Oncol (2000) 1.01
Long chain fatty acyl-CoA synthetase 5 expression is induced by insulin and glucose: involvement of sterol regulatory element-binding protein-1c. Biochimie (2005) 1.00
Invasive fungal infections in solid organ transplant recipients. Clin Microbiol Infect (2014) 1.00
The use of ABO-incompatible grafts in liver transplantation: a life-saving procedure in highly selected patients. Transplantation (1995) 0.99
Discrete brain areas express the insulin-responsive glucose transporter GLUT4. Brain Res Mol Brain Res (1996) 0.99
Changes in 18F-FDG tumor metabolism after a first course of neoadjuvant chemotherapy in breast cancer: influence of tumor subtypes. Ann Oncol (2012) 0.99
Long-term follow-up after liver transplantation for autoimmune hepatitis: evidence of recurrence of primary disease. J Hepatol (1999) 0.97
Tyrosine kinase inhibition in renal cell carcinoma and gastrointestinal stromal tumours: case reports. Ann Oncol (2009) 0.97
Increased insulin sensitivity and responsiveness during lactation in rats. Am J Physiol (1986) 0.97
A risk model for thrombocytopenia requiring platelet transfusion after cytotoxic chemotherapy. Blood (1998) 0.97
Body composition, energy expenditure, and plasma metabolites in long-term fasting geese. Am J Physiol (1981) 0.97
Ketone body transport in the human neonate and infant. J Clin Invest (1986) 0.96
Disseminated toxoplasmosis, resulting from infection of allograft, after orthotopic liver transplantation: usefulness of quantitative PCR. J Clin Microbiol (2002) 0.96
Adipocyte cholesterol balance in obesity. Biochem Soc Trans (2004) 0.96
Site-specific regulation of gene expression by n-3 polyunsaturated fatty acids in rat white adipose tissues. J Lipid Res (1997) 0.96
G388R mutation of the FGFR4 gene is not relevant to breast cancer prognosis. Br J Cancer (2004) 0.96
Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer. J Clin Oncol (1995) 0.95
Efficacy and safety of docetaxel (Taxotere) in heavily pretreated advanced breast cancer patients: the French compassionate use programme experience. Eur J Cancer (1999) 0.95
Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration. Eur J Cancer (2002) 0.95
Phase I and pharmacokinetic study of E7070, a novel sulfonamide, given at a daily times five schedule in patients with solid tumors. A study by the EORTC-early clinical studies group (ECSG). Ann Oncol (2001) 0.95